CYTK – cytokinetics, incorporated (US:NASDAQ)
Stock Stats
News
Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus [Yahoo! Finance]
Form 4 CYTOKINETICS INC For: Apr 07 Filed by: Malik Fady Ibraham
Form 144 CYTOKINETICS INC Filed by: Malik Fady Ibraham
Form 144 CYTOKINETICS INC Filed by: Blum Robert I
Form 4 CYTOKINETICS INC For: Apr 01 Filed by: Blum Robert I
Form 144 CYTOKINETICS INC Filed by: Callos Andrew
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.